Tevard Biosciences is pioneering tRNA therapeutics to find lifelong cures for patients with rare genetic diseases. Some genetic diseases are caused by premature stop codons in mRNA chains. Tevard is developing two unique tRNA-based therapies that can insert a normal amino acid at the premature stop codon. As many diseases share the same premature stop codon, Tevard can use their patented tRNAs to treat multiple diseases. In addition, Tevard’s approach does not cause permanent changes in the genome. Currently, they are developing their technology to treat patients with Dravet syndrome.

Tevard Biosciences

Founded: 2017
Location: Cambridge, MA
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Dravet syndrome
Drug types: GEN, RAR, CNS, PED
Lead product: Undisclosed
Funding: not disclosed

Drug notes:

About:

Jobs: